A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant

被引:28
作者
Iyer, Sunil S.
Barr, William H.
Dance, Mario E.
Coleman, Peter R.
Karnes, H. Thomas
机构
[1] Virginia Commonwealth Univ, Sch Pharm, Dept Pharmaceut, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Sch Pharm, Ctr Drug Studies, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Div Anim Res, Richmond, VA 23298 USA
[4] Coleman Inst, Richmond, VA 23221 USA
关键词
naltrexone implant; modified hanks' balanced salts solution; capillary and flow-through devices; in vitro release testing;
D O I
10.1016/j.ijpharm.2007.03.032
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This research is based on the recognized need for an in vitro release method for drug implants that better simulate physiological conditions at the site of implantation ('biorelevance'). In this paper, we describe the evaluation of a 'biorelevant' approach for in vitro drug release testing of a biodegradable implant of naltrexone in a pre-clinical stage of development. A miniature, capillary cell culture device was modified and tested as a biorelevant alternative for a standard commercially available flow-through cell. The real-time data generated through 90 days indicated a 48% lower rate of release for the capillary system. The profiles using both systems followed zero-order kinetics after an initial period of burst release. In vitro release data from the capillary device resulted in a 1-to-1 correlation with dog plasma pharmacokinetic data, and furthermore, the capillary device potentially simulated the lag-time in absorption more effectively than the flow-through cell. Scanning electron micrographs revealed that the sheath was continuous with no signs of cracks at the end of in vitro and in vivo studies. However, at the interface of the sheath and the core, intercalating, "finger-like" projections were observed consistent with penetration of the medium. No macroscopic or clinical toxicity signs were observed during the in vivo implantation study. (c) 2007 Elsevier B.V All rights reserved.
引用
收藏
页码:104 / 118
页数:15
相关论文
共 64 条
[1]  
Agrawal CM, 1997, J BIOMED MATER RES, V38, P105, DOI 10.1002/(SICI)1097-4636(199722)38:2<105::AID-JBM4>3.0.CO
[2]  
2-U
[3]   Kinetics and mechanism of release from glyceryl monostearate-based implants: Evaluation of release in a gel simulating in vivo implantation [J].
Allababidi, S ;
Shah, JC .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (06) :738-744
[4]  
ANDERSON JM, 1994, EUR J PHARM BIOPHARM, V40, P1
[5]   Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid polyglycolic acid copolymers [J].
Athanasiou, KA ;
Niederauer, GG ;
Agrawal, CM .
BIOMATERIALS, 1996, 17 (02) :93-102
[6]  
BALLARD BE, 1961, THESIS U CALIFORNIA
[7]   Vivitrex®, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats [J].
Bartus, RT ;
Emerich, DF ;
Hotz, J ;
Blaustein, M ;
Dean, RL ;
Perdomo, B ;
Basile, AS .
NEUROPSYCHOPHARMACOLOGY, 2003, 28 (11) :1973-1982
[8]  
BENET LZ, 1990, MODERN PHARMACEUTICS, V40, P181
[9]   IN-VIVO DEGRADATION AND BIOCOMPATIBILITY STUDY OF IN-VITRO PRE-DEGRADED AS-POLYMERIZED POLYLACTIDE PARTICLES [J].
BERGSMA, JE ;
ROZEMA, FR ;
BOS, RRM ;
BOERING, G ;
DEBRUIJN, WC ;
PENNINGS, AJ .
BIOMATERIALS, 1995, 16 (04) :267-274
[10]   Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases [J].
Brewer, C .
ADDICTION BIOLOGY, 2002, 7 (03) :321-323